Key facts
- LifeLens’s last known valuation is $233.4M (Nov 2025).
- It has raised $74.6M; the latest was Later Stage VC ($15.1M) in Nov 2025.
- Notable investors include Brightstone Venture Capital, Highcroft Capital, Medical Technology Enterprise Consortium, Next Chapter Ventures, Paragon Equity Partners — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for LifeLens
- ·The full record, as it builds
Funding rounds
No funding rounds for LifeLens are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LifeLens
Developer of physiologic monitoring devices designed to summarize a patient's physiologic health in real-time. The company's wireless electrocardiogram (ECG) monitor is indicated for use on patients who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, lightheadedness, pre-syncope, syncope, fatigue, chest pain, or anxiety, enabling patients to get technologies for fidelity physiologic monitoring.
- Sector
- Healthcare
- HQ
- Ivyland, PA, United States
- Founded
- 2014
- Employees
- 90
- Website
- lifelenstech.com/
- Ownership
- Privately Held (backing)
LifeLens doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LifeLens shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LifeLens in its N-PORT filings yet. We sweep new filings monthly.